
PRAX Stock Forecast & Price Target
PRAX Analyst Ratings
Bulls say
Praxis Precision Medicine has exhibited substantial growth in research and development (R&D) expenses, with a striking 206.1% year-over-year increase, highlighting the company's commitment to advancing its clinical-stage product candidates, including ulixacaltamide and vormatrigine. The firm is poised for potential growth as the peak market share for vormatrigine is anticipated to rise based on its favorable clinical profile, which could enhance patient treatment persistence and drive earlier usage in therapeutic lines. Additionally, with a robust financial position and plans for multiple studies into 2025, Praxis is well-positioned to capitalize on increasing diagnosis and treatment rates in conditions like essential tremor, which may expand its patient population and contribute to long-term growth.
Bears say
Praxis Precision Medicine is facing significant challenges that could adversely impact its stock performance, primarily stemming from clinical and regulatory setbacks, which have already led to the halting of the ulixacaltamide study due to concerns regarding its efficacy. The company's financial situation is further strained by an operating loss that widened to $64.0 million in the latest quarter, exceeding prior estimates, while the removal of ulixacaltamide sales from valuation models sharply reduced expected revenue. Additionally, the reliance on the success of its pipeline products in a competitive landscape raises concerns that even if approved, these therapies may struggle to gain market acceptance, leading to disappointing sales.
This aggregate rating is based on analysts' research of Praxis Precision Medicines and is not a guaranteed prediction by Public.com or investment advice.
PRAX Analyst Forecast & Price Prediction
Start investing in PRAX
Order type
Buy in
Order amount
Est. shares
0 shares